These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16193100)

  • 1. Control of cancers by combining antiangiogenesis and cancer immunotherapy.
    Moniz M; Yeatermeyer J; Wu TC
    Drugs Today (Barc); 2005 Jul; 41(7):471-94. PubMed ID: 16193100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promising early results for immunotherapy-antiangiogenesis combination.
    Garber K
    J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25421345
    [No Abstract]   [Full Text] [Related]  

  • 3. Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges.
    Li SJ; Chen JX; Sun ZJ
    Cancer Commun (Lond); 2021 Sep; 41(9):830-850. PubMed ID: 34137513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
    Grothey A; Ellis LM
    Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.
    Everson RG; Graner MW; Gromeier M; Vredenburgh JJ; Desjardins A; Reardon DA; Friedman HS; Friedman AH; Bigner DD; Sampson JH
    Expert Rev Anticancer Ther; 2008 May; 8(5):717-32. PubMed ID: 18471045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment.
    Gjerstorff MF; Burns J; Ditzel HJ
    Expert Opin Biol Ther; 2010 Jul; 10(7):1061-75. PubMed ID: 20420535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen.
    Cheng WF; Hung CF; Chai CY; Hsu KF; He L; Ling M; Wu TC
    J Clin Invest; 2001 Sep; 108(5):669-78. PubMed ID: 11544272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic agents in cancer therapy.
    Lenz HJ
    Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):17-25. PubMed ID: 15934499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic gene modified cell based cancer vaccines.
    Kozłowska A; Mackiewicz J; Mackiewicz A
    Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis.
    Cheng WF; Hung CF; Chen CA; Lee CN; Su YN; Chai CY; Boyd DA; Hsieh CY; Wu TC
    Vaccine; 2005 May; 23(29):3864-74. PubMed ID: 15893626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Future approaches in immunotherapy.
    Rini B
    Semin Oncol; 2014 Oct; 41 Suppl 5():S30-40. PubMed ID: 25438998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapies of cancer: angiogenesis inhibition seems not enough.
    Roodink I; Leenders WP
    Cancer Lett; 2010 Dec; 299(1):1-10. PubMed ID: 20889254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
    Xia D; Moyana T; Xiang J
    Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination approach to anti-angiogenic treatment of cancer.
    Wentink MQ; Huijbers EJ; de Gruijl TD; Verheul HM; Olsson AK; Griffioen AW
    Biochim Biophys Acta; 2015 Apr; 1855(2):155-71. PubMed ID: 25641676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiangiogenesis and vascular endothelial growth factor/vascular endothelial growth factor receptor targeting as part of a combined-modality approach to the treatment of cancer.
    O'Reilly MS
    Int J Radiat Oncol Biol Phys; 2007; 69(2 Suppl):S64-6. PubMed ID: 17848299
    [No Abstract]   [Full Text] [Related]  

  • 19. Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.
    Osada T; Nagaoka K; Takahara M; Yang XY; Liu CX; Guo H; Roy Choudhury K; Hobeika A; Hartman Z; Morse MA; Lyerly HK
    J Immunother; 2015 May; 38(4):155-64. PubMed ID: 25839441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colorectal cancer and antiangiogenic therapy: what can be expected in clinical practice?
    Mancuso A; Sternberg CN
    Crit Rev Oncol Hematol; 2005 Jul; 55(1):67-81. PubMed ID: 15890525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.